Immunophenotypic characteristics and clinical relevance of CD56+ and CD56- extranodal nasal-type natural killer/T-cell lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 3, 2011, Pages 417-424

  Li, Ye Xiong ^a   Wang, Hua ^a,b   Feng, Xiao Li ^a   Liu, Qing Feng ^a   Wang, Wei Hu ^a   Lv, Ning ^a   Jin, Jing ^a   Wang, Shu Lian ^a   Liu, Yue Ping ^a   Fang, Hui ^a   Song, Yong Wen ^a   Liu, Xin Fan ^a   Zhou, Li Qiang ^a   Wang, Zhao Yang ^a   Yu, Zi Hao ^a  

^a CANCER HOSPITAL   (China)

^b Cancer Hospital of Jiangxi Province   (China)

Author keywords

chemotherapy; immunophenotype; NK T cell lymphoma; prognosis; radiotherapy

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANZYME B; KI 67 ANTIGEN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; CHILD; COHORT STUDIES; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79951714365     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.543718     Document Type: Article

References (48)

1. Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005;16:206-214.
2. Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007;109:2183-2189. (Pubitemid 46348221)
3. Kim K, Chie EK, Kim CW, et al. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol 2005;35:1-5. (Pubitemid 40450547)
4. Barrionuevo C, Zaharia M, Martinez MT, et al. Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol 2007;15:38-44. (Pubitemid 46673314)
5. Kim TM, Lee SY, Jeon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 2008;19:1477-1484.
6. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181-189. (Pubitemid 46630511)
7. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood 2009;113:3931-3937.
8. Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005;41:1402-1408. (Pubitemid 40826463)
9. Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood 2008;112:3057-3064.
10. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612-618. (Pubitemid 46630424)
11. Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res 2009;15:2905-2912.
12. Mraz-Gernhard S, Natkunam Y, Hoppe RT, et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol 2001;19:2179-2188. (Pubitemid 32366972)
13. Assaf C, Gellrich S, Whittaker S, et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol 2007;60:981-989. (Pubitemid 47441929)
14. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-26. (Pubitemid 28304493)
15. Aviles A, Diaz NR, Neri N, et al. Angiocentric nasal T/natural killer cell lymphoma: a single center study of prognostic factors in 108 patients. Clin Lab Haematol 2000;22:215-220.
16. Wang ZY, Li YX, Wang WH, et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood 2009;114:4771-4776.
17. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol 2009;27:6027-6032.
18. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009;27:5594-5600.
19. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasal type. In Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp 285-288.
20. Harabuchi Y, Imai S, Wakashima J, et al. Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies. Cancer 1996;77:2137-2149. (Pubitemid 26142062)
21. Ohsawa M, Nakatsuka H, Kanno H, et al. Immunophenotypic and genotypic characterization of nasal lymphoma with polymorphic reticulosis morphology. Int J Cancer 1999;81:865-870. (Pubitemid 29249969)
22. Yoon TY, Lee HT, Chang SH. Nasal-type T/natural killer cell angiocentric lymphoma, Epstein-Barr virus-associated, and showing clonal T-cell receptor gamma gene rearrangement. Br J Dermatol 1999;140:505-508.
23. Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 2001;97:708-713. (Pubitemid 32113404)
24. Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol 2004;17:1097-1107. (Pubitemid 39128236)
25. Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000;89:2106-2116.
26. Ko YH, Cho EY, Kim JE, et al. NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status. Histopathology 2004;44:480-489. (Pubitemid 38725677)
27. Harabuchi Y, Takahar M, Kishibe K, et al. Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features. Int J Clin Oncol 2009;14:181-190.
28. Schwartz EJ, Molina-Kirsch H, Zhao S, et al. Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray. An analysis of 84 cases. Am J Clin Pathol 2008;130:343-351.
29. Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998;16:70-77. (Pubitemid 28041581)
30. Kim GE, Koom WS, Yang WI, et al. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck 2004;26:584-593. (Pubitemid 38857099)
31. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994. (Pubitemid 23307906)
32. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-1253. (Pubitemid 29162950)
33. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic Tcell and natural killer cell lymphomas. Semin Hematol 2003;40:175-184. (Pubitemid 36842595)
34. Hasserjian RP, Harris NL. NK-cell lymphomas and leukemias: a spectrum of tumors with variable manifestations and immunophenotype. Am J Clin Pathol 2007;127:860-868.
35. Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010;21:1032-1040.
36. Cheung MM, Chan JK, Lau WH, et al. Early stage nasal T/NK-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54:182-190.
37. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 2004;103:216-221.
38. Ohno T, Yamaguchi M, Oka K, et al. Frequent expression of CD3 epsilon in CD3 (Leu 4)-negative nasal T-cell lymphomas. Leukemia 1995;9:44-52.
39. Zeromski J, Nyczak E, Dyszkiewicz W. Significance of cell adhesion molecules, CD56/NCAM in particular, in human tumor growth and spreading. Folia Histochem Cytobiol 2001;39(Suppl. 2):36-37. (Pubitemid 34070751)
40. Korja M, Jokilammi A, Salmi TT, et al. Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma. BMC Cancer 2009;9:57.
41. Harrington AM, Hari P, Kroft SH. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. Am J Clin Pathol 2009;132:60-66.
42. Kim SJ, Kim BS, Choi CW, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal-type. Ann Oncol 2007;18:1382-1387. (Pubitemid 47307226)
43. Yasuda H, Sugimoto K, Imai H, et al. Expression levels of apoptosis-related proteins and Ki-67 in nasal NK/T-cell lymphoma. Eur J Haematol 2008;82:39-45.
44. Liu X, Wang B, Ma X, Guo Y. NK-κB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type. Jpn J Clin Oncol 2009;39:418-424.
45. Bekkenk MW, Jansen PM, Meijer CJLM, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004;15:1097-1108. (Pubitemid 39089788)
46. Yoshino T, Nakamura S, Suzumiya J, et al. Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma. Br J Haematol 2002;118:482-487. (Pubitemid 34994653)
47. Lin CW, Yang JY, Chuang YC, et al. Presence of restricted killer immunoglobulin-like receptor repertoire and monoclonal T-cell receptor g rearrangement as evidence of mixed NK/T-cell differentiation in a subset of sinonasal lymphomas. Lab Invest 2003;83:55-64.
48. Huang Y, de Reynies A, de Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal-type. Blood 2010;115:1226-1237.